Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amphastar Pharma excels in Q4 with strong revenue growth and product success

Amphastar Pharma's Q4 2022 performance reflects strong revenue growth, profitability, and product success, positioning the company well for future growth.
The company's focus on high-margin products, FDA approvals, and strategic investments in marketing and R&D underscore its commitment to innovation and market competitiveness.
While facing challenges in sustaining growth and managing costs, Amphastar Pharma has opportunities for expansion through product development, market penetration, and strategic initiatives.

Amphastar Pharma excels in Q1 2023, eyes growth opportunities

Amphastar Pharma's Q1 2023 showcased robust financial performance, driven by revenue growth and strategic product initiatives.
While facing challenges in market dynamics and margin management, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial strength, Amphastar Pharma demonstrates resilience and potential for sustained success.

Amphastar Pharma excels in Q2 with revenue growth and innovation

Amphastar Pharma's Q2 2023 performance reflects strong revenue growth, improved profitability, and operational efficiency, underpinned by robust sales across key products.
While facing challenges such as FDA approval delays and pipeline setbacks, the company's strategic focus on proprietary products and innovation presents opportunities for sustained growth.
By capitalizing on market demand, enhancing margins, and advancing its product pipeline, Amphastar is poised to navigate challenges and capitalize on opportunities for long-term success.

Amphastar Pharma excels in Q3 with robust revenue growth

Amphastar Pharma delivered impressive financial results in Q3 2023, marked by significant revenue growth and profitability improvements.
While facing challenges in sustaining rapid sales growth and managing debt obligations, the company's strategic focus on product expansion and market presence presents growth opportunities.
Overall, Amphastar Pharma's strong performance, diverse product portfolio, and financial stability position it well for future growth and value creation for stakeholders.

Amphastar Pharma excels in Q4 2023, eyes growth opportunities

Amphastar Pharma's Q4 2023 performance reflects robust growth in revenues, profit, and net income, driven by strategic focus and product demand.
While facing challenges like lower gross margins and capacity expansions, the company is poised for growth through innovation and market opportunities.
Opportunities lie in R&D advancements, product launches, and financial strength, positioning Amphastar Pharma for continued success and expansion.

Amphastar Pharma excels in Q1 2024, eyes growth through innovation

Amphastar Pharma's Q1 2024 showcases strong financial performance and strategic focus on product innovation and market expansion. While facing challenges in pricing and regulatory landscape, the company is poised for growth through new product launches and market penetration strategies.

Amphastar Pharma reports revenue growth amidst margin challenges and regulatory hurdles

Amphastar Pharma's Q3 performance showed revenue growth driven by key products.
While facing challenges in net income and margins, the company aims for sustainable growth.
Opportunities lie in product launches, market expansion, and regulatory progress.
Overall, Amphastar Pharma navigates financial challenges with strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $55.61, denoting a +1.85% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

Arcutis Biotherapeutics

Nkarta, Inc.

The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.

Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know

Abercrombie & Fitch

Cameco

CyberArk Software

LendingTree

Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.

5 Top Growth Stocks to Buy as Recession Fears Subside

American Public Education

Gigacloud Tech

Oceaneering

Here are four top-performing liquid stocks, American Public Education (APEI), Amphastar Pharmaceuticals (AMPH), GigaCloud (GCT) and Oceaneering International (OII), which investors can add to their portfolio to boost returns.

Snap these 4 Top-Ranked Liquid Stocks to Drive Solid Returns

Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $62.74, signifying a -1.12% move from its prior day's close.

Amphastar Pharmaceuticals (AMPH) Stock Drops Despite Market Gains: Important Facts to Note

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST.

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amphastar Pharmaceuticals (AMPH) Is Up 1.53% in One Week: What You Should Know

Fluor

Puma Biotechnology

Vimeo

Building a portfolio comprising stocks with favorable liquidity is the way to go for investors seeking healthy returns.

4 Promising Liquid Stocks to Boost Your Portfolio in 2024

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts Think Amphastar (AMPH) Is a Good Investment: Is It?

Aquestive Therapeutics Inc

Centessa Pharmaceuticals PLC

Journey Medical Corp

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Beacon Roofing Supply

Shift4 Payments

Hooker Furniture

Hilltop Holdings

AMPH, FOUR, BECN, HOFT and HTH are five stocks with explosive relative price strength.

5 Good Opportunities on Relative Price Strength Strategy

ImmunoGen

Neurocrine Biosciences

Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments, not only to attack important diseases but also to prevent them.

3 Stocks at the Forefront of Medical Innovation

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock

Eli Lilly

AMPH stock has doubled so far this year and is in a buy zone again. It earlier bought Eli Lilly's emergency diabetes drug which can drive future growth.

Will Eli Lilly's Emergency Diabetes Drug Give Amphastar Wings?

Limbach Holdings

Insight Enterprises

Carrols Restaurant Group

After a strong 2023, we expect the Nasdaq to log gains in 2024. Top-ranked Nasdaq stocks GigaCloud Technology Inc (GCT), Carrols Restaurant Group (TAST), Limbach (LMB), Amphastar Pharmaceuticals (AMPH) and Insight Enterprises Inc (NSIT) could emerge as winning picks.

What's in Store for Nasdaq in 2024? 5 Top Picks

Dropbox

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX) and GigaCloud Technology Inc. (GCT), which investors can add to their portfolio for solid gains.

Snap These 4 Top-Performing Liquid Stocks for Strong Returns

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)

Are You Looking for a Top Momentum Pick? Why Amphastar Pharmaceuticals (AMPH) is a Great Choice

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this year from Eli Lilly.

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

This biotech stock is in a base after the company produced triple-digit earnings growth. AMPH stock is poised for a move.

This Biotech Stock Nears A Buy Point After 200% Profit Growth

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.

4 Top-Performing Liquid Stock Picks for Robust Returns

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Amphastar (AMPH) Is Considered a Good Investment by Brokers: Is That True?

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST.

News for Amphastar Pharma Stock (AMPH)